Latest news
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 12:00:00 GMTTheriva’s Six-Patient Cancer Trial Is Designed to Test Repeat Virus Dosing - Stock TitanStock Titan · Thu, 06 Aug 2026 12:00:00 GMTDispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 12:00:00 GMTPriovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 11:00:00 GMTObsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma - biospace.combiospace.com · Thu, 06 Aug 2026 03:07:48 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2a-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 02:05:27 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - Banning Record GazetteBanning Record Gazette · Thu, 06 Aug 2026 00:00:00 GMTSystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - PR NewswirePR Newswire · Wed, 05 Aug 2026 12:00:00 GMT